New hope for hepatitis b moms: drug may shield babies from infection
NCT ID NCT05853718
First seen Oct 31, 2025 · Last updated Jun 20, 2026 · Updated 28 times
Summary
This study tests the drug TAF in 50 pregnant women with chronic hepatitis B to see if it safely reduces the virus and prevents passing it to their babies. Women take one tablet daily from week 28-32 of pregnancy until delivery. Researchers will measure drug levels in blood and breast milk, check for birth defects, and test infants for hepatitis B at 7-12 months old.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hangzhou First People's Hospital
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenofovir alafenamide (TAF) tablets
What this could lead to
If successful, this could provide a safe way to prevent passing hepatitis B from mother to baby during childbirth.
What could go wrong
This is a small, early-phase study with only 50 participants, so results may not apply to all. Risks include unknown effects on the infant and potential side effects from the drug.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.